Old arthritis drug paired with immune suppressant shows promise against tough lung cancers
NCT ID NCT01737502
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. The trial is now complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- auranofin and sirolimus
- What this could lead to
- If it works, this could point toward a new treatment option for advanced lung cancer patients who have run out of standard therapies.
- What could go wrong
- This was a small, early-phase trial with only 29 participants, so results may not apply to all patients. The combination may cause significant side effects and may not effectively control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI be a Pathologist's second opinion?
- Personalized cancer care: genetic analysis may unlock targeted treatments for advanced lung cancer
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Blood tests could unlock early clues for three major lung diseases
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- Genetic roadmaps for advanced cancer: study tests whether expert navigation boosts targeted therapy use